Navigation Links
John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.
Date:4/4/2011

PARSIPPANY, N.J., April 4, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced today that John P. Gargiulo has been appointed President and CEO of the company. Effective today, Mr. Gargiulo succeeds Joseph P. Pieroni who is retiring after leading Daiichi Sankyo Group's U.S. commercial operations for the past 14 years.

"John's experiences within the pharmaceutical industry for the past 25 years have prepared him well for his new role and responsibility," said Joseph Pieroni, former President and CEO of Daiichi Sankyo, Inc. "He has been instrumental in building and shaping the company since its inception in 1996, and has touched nearly every aspect of our business operations. His broad industry experience enabled him to learn and grow the commercial operations organization."

Mr. Gargiulo most recently served as Senior Vice President of Commercial Operations, where he oversaw U.S. Marketing, Supply Chain, Managed Markets and New Product Planning. After joining the predecessor organization, Sankyo, in 1995, Gargiulo was instrumental in advancing DSI from a joint venture with Parke-Davis to its current status as a leader in hypertension therapy and with an emerging presence in thrombosis and oncology.

"Joe has been a great leader, and has made DSI a successful company by driving excellence through innovation, integrity and accountability -- and by modeling these core company values himself," said Gargiulo, President and CEO of Daiichi Sankyo, Inc. "I am excited about leading DSI through our next company milestones, and fostering a continuing vision of employee excellence that will drive DSI growth and success."

Prior to joining DSI, Gargiulo held several positions at Lederle Laboratories. He currently serves on the Board of Directors of the national industry trade association, the Pharmaceutical Research and Manufacturers Association (PhRMA), and the National Pharmaceutical Council (NPC), an industry trade group focused on evidence-based medicine.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group.  For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.


'/>"/>
SOURCE Daiichi Sankyo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedShape Solutions, Inc. Named ATDC Graduate
2. CardioMEMS, Inc. Named a TAG Top 10 Innovative Technology Company
3. Varian Medical Systems to Exhibit New TrueBeam™ System for Image-Guided Radiotherapy at ChinaMed Exhibition in Beijing
4. Netsmart Technologies Named NACo Premier Partner of the Year
5. R. Lindholm Named to Crux Biomedical Board
6. Ferring Pharmaceuticals, Inc. Congratulates R&B and Pop Icon Gloria Gaynor, Named Woman of the Year by Arthritis Foundation
7. Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader
8. Living Medical eTextbook iPhone App from Projects In Knowledge® Named to Top 20 List of Free Medical Apps
9. Dawn Phillips Named as Vice President, Business Development for Catastrophic & Home Health Services
10. Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomens Association
11. Dynatronics Named Contract Supplier to Amerinets 50,000 Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/29/2016)... -- Automation is one of the best ... growing demands for productivity in speed, accuracy, throughput and ... already adept of a wide range of functions that ... Instrumentation continues to evolve, and is poised to tackle ... years ago. Originally used mostly by the big pharmaceutical ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s ... Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over 400 ... 5k Run and Walk and 1-mile walk were held to increase awareness about ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... ... type of skin cancer. Although only about 1 percent of skin cancer cases are melanoma, ... are expected to die of melanoma this year. The risk increases with age, and while ... diagnosed cancers in young women. A recent breakthrough in genetic studies may give doctors the ...
(Date:4/29/2016)... Grants Pass, OR (PRWEB) , ... April 29, 2016 , ... ... nutritionists suggest dinner as the meal to miss. That was among the many new ... True Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... media enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, ... as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors ...
Breaking Medicine News(10 mins):